GlassScriptPhysician profile
Amudhan Jyothidasan
NPI 1619282365
$4,664.86
in general payments reported to CMS, 2019-2025
30 companies · $721 in 2025
The $721 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $172 · 2021: $178 · 2022: $970 · 2023: $971 · 2024: $1,080 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,773.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,160.48 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Amgen INC. | $877.45 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.77 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $308.71 | 2019-2025 | |
| Edwards Lifesciences Corporation | $229.58 | 2019-2023 | Pascal |
| Pfizer INC. | $229.53 | 2023-2025 | |
| Abiomed | $212.98 | 2021-2024 | Impella |
| Philips North America LLC | $200.53 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, Diagnostic Ecg Service, Extended Holter |
| Impulse Dynamics (USA) INC. | $109.97 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $106.07 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.67 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $90.56 | 2023-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $83.02 | 2019-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $79.07 | 2022-2025 | Verquvo |
| Novo Nordisk INC | $74.91 | 2025 | Wegovy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $68.87 | 2023-2024 | |
| Medtronic, INC. | $66.37 | 2021-2023 | Cobalt Dr Mri Surescan |
| Astellas Pharma US INC | $59.99 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $46.17 | 2023 | Arcalyst |
| Cardiovascular Systems INC. | $31.83 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $30.04 | 2024 | Opsumit, Uptravi |
| Cashflow Solutions, LLC | $25.70 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Abbott Laboratories | $24.91 | 2023 | Amplatzer |
| Angiodynamics, INC. | $22.52 | 2023 | Venacure 1470 Pro |
| Bayer Healthcare Pharmaceuticals INC. | $21.64 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.07 | 2023 | Inpefa |
| Agepha Pharma Fz LLC | $19.75 | 2025 | Lodoco |
| Chiesi USA, INC. | $19.08 | 2021 | |
| Bridgebio Pharma, INC. | $16.88 | 2025 | Attruby |
| Vital Connect, INC | $16.74 | 2024 | Vitalpatch Rtm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amudhan Jyothidasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.